ArticleJournal of clinical pathology1994
Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.
Article in Journal of clinical pathology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 76 citations in OpenAlex.
- A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.Gynecologic oncology · 2012Trial
- Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer.Cancer science · 2004Trial
- Biology of PEST-containing nuclear proteins as potential targets in ovarian cancer (Review).Oncology letters · 2026Review
- Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.Journal of hematology & oncology · 2024Article
- c-MYC and Epithelial Ovarian Cancer.Frontiers in oncology · 2021Review
- Overexpression of RASAL1 Indicates Poor Prognosis and Promotes Invasion of Ovarian Cancer.Open life sciences · 2019Article
- Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.Oncotarget · 2018Article
- Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obeseOncotarget · 2017Article
- Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer.Oncotarget · 2017Article
- Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.Oncotarget · 2017Article
- Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.Theranostics · 2015Article
- Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.Genes & cancer · 2014Article
- Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.International journal of molecular sciences · 2012Review
- Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.Cancer research · 2010Article
- EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.Current protein & peptide science · 2010Review
- Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Journal of oncology · 2010Article
- Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines.Oncogene · 2008Article
- Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival.Molecular pathology : MP · 1997Article
- Glucocorticoid and estrogen receptors have elevated activity in human endometrial and ovarian tumors as compared to the adjacent normal tissues and recognize sequence elements of the H-ras proto-oncogene.Japanese journal of cancer research : Gann · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo assess whether the overexpression of five dominant oncogene encoded proteins is crucial to the pathogenesis of ovarian carcinoma and whether this provides any useful prognostic information.
methodsThe expression of the insulin-like growth factor 1 receptor (ILGFR 1), epidermal growth factor receptor (EGFR), and the c-erbB-2, c-ras, and c-myc products was studied by multiparameter flow cytometry in 80 patients with epithelial ovarian cancer for whom long term follow up was available.
resultsOverexpression of ILGFR 1, EGFR, c-erbB-2, c-ras and c-myc was found in, respectively, nine of 80 (11%), 10 of 80 (12%), 19 of 80 (24%), 16 of 80 (20%) and 28 of 80 (35%) ovarian carcinomas. The levels of expression of ILGFR 1, EGFR, c-erbB-2 and c-ras were significantly higher in the tumours of patients with recurrent or persistent disease after chemotherapy than in the tumours of patients at initial presentation (p < 0.02). Multivariate analysis showed that residual tumour (p < 0.001), FIGO stage (p = 0.002), EGFR overexpression (p = 0.030) and previous chemotherapy (p = 0.034) were independent variables for predicting survival.
conclusionsOverexpression of these oncoproteins only occurs in a small proportion of ovarian carcinomas but may have an important role in the progression of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.